Curriculum Vitae



Namki Hong

Associate Professor
Department of Internal Medicine, Yonsei University College of Medicine, Korea

Educational Background & Professional Experience

2009.02	Yonsei University College of Medicine, Seoul, South Korea, M.D., Medicine
2012.08	Graduate School of Public Health, Yonsei University, Seoul, South Korea, M.P.H., Public Health/Epidemiology
2022.02	Graduate School of Medicine, Yonsei University, Seoul, South Korea, Ph.D., Medical Science
2011.06	United States Medical Licensing Examination (step 1, step 2 CK/CS, step 3), ECFMG Certified, Medicine
2017.02	Severance Hospital (Yonsei Univ. affiliated), Seoul, South Korea, Resident, Internal Medicine
2019.02	Severance Hospital (Yonsei Univ. affiliated), Seoul, South Korea, Clinical Fellow, Endocrinology

Research Interests

1) Musculoskeletal Aging in Cohort Studies
2) Discovering new biomarkers in Metabolic bone disease
3) Cardiometabolic Health
4) Artificial Intelligence and Imaging–Based Precision Phenotyping in Musculoskeletal Aging
5) Entropy and Homeostatic Dysregulation in Aging

Publications

1. Hong N, Cho SW, Kim J, et al. Entropy, Assessed by Homeostatic Dysregulation on Electrocardiograms Predicts Fracture and Mortality. Aging Cell. 2025:e70227.
2. Cho SW, Hong N, Kim KM, et al. Spine age estimation using deep learning in lateral spine radiographs and DXA VFA to predict incident fracture and mortality. npj Aging. 2025;11(1):83.
3. Hong N, Cho SW, Lee YH, et al. Deep learning–based identification of vertebral fracture and osteoporosis in lateral spine radiographs and DXA vertebral fracture assessment to predict incident fracture. Journal of Bone and Mineral Research. 2025;40(5):628–38.
4. Hong N, Cho SW, Shin S, et al. Deep–Learning–Based Detection of Vertebral Fracture and Osteoporosis Using Lateral Spine X–Ray Radiography. J Bone Miner Res. 2023;38(6):887–95.
5. Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y. Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Miner Res. 2025;40(2):184–92.